Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Ferrari NV — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Ferrari NV trades at $406.75 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 7.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Ferrari NV pays a 1.04% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | RACE | |
|---|---|---|
Market Cap | $9.39B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $504.09 |
52-Week Low | $241.71 | $314.63 |
Enterprise Value | $9.14B | $73.60B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Ferrari (RACE) trades at $412.26, up 1.22% on the day, near its pivot point of $412. The stock exhibits strong bullish momentum in moving averages and has beaten earnings estimates for three consecutive quarters. Revenue and net income have grown steadily, with 2025 revenue reaching $7.15B and net income $1.60B, though valuation ratios like a P/E of 38.45 are elevated. Recent news highlights robust demand, particularly for vehicle personalization, and the company raised its 2026 guidance following a strong Q2.
The outlook remains positive given strong fundamentals, bullish analyst sentiment, and raised guidance, but risks include high valuation multiples, potential economic sensitivity, and execution challenges with new models like the Luce EV. The consensus price target of $462.67 suggests ~12% upside, supported by institutional confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
